Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Open access

Abstract

Significance: Improving survival of patients with glioblastoma (GBM) using antiangiogenic therapy remains a challenge. In this study we show that dual blockade of angiopoietin-2 and vascular endothelial growth factor delays tumor growth and enhances survival benefits through reprogramming of tumor-associated macrophages toward an antitumor phenotype as well as by pruning immature tumor vessels. The antitumor immunomodulatory potential of this dual blockade supports clinical testing of this approach for GBM with other immunotherapeutic approaches such as checkpoint blockers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1525360113

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 1

  1. 10.1002/(SICI)1097-0215(19990702)82:1<12::AID-IJC3>3.0.CO;2-O · doi:10.1002/(sici)1097-0215(19990702)82:1<12::aid-ijc3>3.0.co;2-o

Cited by

See all 357

Metadata

Authors
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., Askoxylakis, V., Taylor, J. W., Lu-Emerson, C., Batista, A., Kirkpatrick, N. D., Jung, K., Snuderl, M., Muzikansky, A., Stubenrauch, K. G., Krieter, O., Wakimoto, H., Xu, L., Munn, L. L., Duda, D. G., Fukumura, D., Batchelor, T. T., & Jain, R. K.
Affiliations
  • Harvard University (US)
  • Tufts University (US)
  • Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114;
  • Roche Pharma AG (Germany) (DE)
Venue
Proceedings of the National Academy of Sciences
Published
2016-04-04
Volume
113
Issue
16
Pages
4476-4481
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2326749252
Cited by
357
References
69
Citations by year
2026: 8 · 2025: 31 · 2024: 29 · 2023: 38 · 2022: 36 · 2021: 50 · 2020: 39 · 2019: 35 · 2018: 40 · 2017: 35 · 2016: 15
FWCI
21.65
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • HHS | National Institutes of Health (P50CA165962, P01CA080124, KCA125440, R01CA126642, R35CA197743, R01CA159258, R01CA096915, R01HL106584, S10-RR027070, T32-CA073479, K12CA090354)
  • U.S. Department of Defense (W81XWH-10-1-0016)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
glioblastoma, angiopoietin-2, vascular endothelial growth factor, bispecific antibodies, anti-VEGF therapy resistance, tumor-associated macrophages, microglia, tumor immune microenvironment, tumor vasculature, tumor growth inhibition, survival
MeSH terms
Animals, Antibodies, Neoplasm, Antineoplastic Agents, Glioblastoma, Humans, Macrophages, Neoplasm Proteins, Neoplasms, Experimental, Ribonuclease, Pancreatic, Antibodies, Bispecific, Xenograft Model Antitumor Assays, Vesicular Transport Proteins, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. https://app.cochat.ai/papers/10.1073/pnas.1525360113
The paper
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., Askoxylakis, V., Taylor, J. W., Lu-Emerson, C., Batista, A., Kirkpatrick, N. D., Jung, K., Snuderl, M., Muzikansky, A., Stubenrauch, K. G., . . . Jain, R. K. (2016). Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1525360113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.